NO924507D0 - Protein fra haemophilus influenzae - Google Patents

Protein fra haemophilus influenzae

Info

Publication number
NO924507D0
NO924507D0 NO924507A NO924507A NO924507D0 NO 924507 D0 NO924507 D0 NO 924507D0 NO 924507 A NO924507 A NO 924507A NO 924507 A NO924507 A NO 924507A NO 924507 D0 NO924507 D0 NO 924507D0
Authority
NO
Norway
Prior art keywords
protein
influenzae
molecular weight
encapsulated
apparent molecular
Prior art date
Application number
NO924507A
Other languages
English (en)
Other versions
NO309721B1 (no
NO924507L (no
Inventor
Arne Forsgren
Original Assignee
Arne Forsgren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20379641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO924507(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arne Forsgren filed Critical Arne Forsgren
Publication of NO924507D0 publication Critical patent/NO924507D0/no
Publication of NO924507L publication Critical patent/NO924507L/no
Publication of NO309721B1 publication Critical patent/NO309721B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1242—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/11—Automated chemical analysis
    • Y10T436/115831—Condition or time responsive
    • Y10T436/116664—Condition or time responsive with automated titrator
NO924507A 1990-05-31 1992-11-24 Fremgangsmåte for fremstilling av et terapeutisk aktivt protein D fra Haemophilus influenzae, DNA-sekvens, rekombinant DNA- molekyl, samt ikke-human vertscelle som er i stand til å produsere et protein av Haemophilus influenzae eller beslektede H NO309721B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9001949A SE466259B (sv) 1990-05-31 1990-05-31 Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
PCT/SE1991/000129 WO1991018926A1 (en) 1990-05-31 1991-02-21 PROTEIN D - AN IgD-BINDING PROTEIN OF HAEMOPHILUS INFLUENZAE

Publications (3)

Publication Number Publication Date
NO924507D0 true NO924507D0 (no) 1992-11-24
NO924507L NO924507L (no) 1992-11-30
NO309721B1 NO309721B1 (no) 2001-03-19

Family

ID=20379641

Family Applications (4)

Application Number Title Priority Date Filing Date
NO924507A NO309721B1 (no) 1990-05-31 1992-11-24 Fremgangsmåte for fremstilling av et terapeutisk aktivt protein D fra Haemophilus influenzae, DNA-sekvens, rekombinant DNA- molekyl, samt ikke-human vertscelle som er i stand til å produsere et protein av Haemophilus influenzae eller beslektede H
NO20003716A NO322330B1 (no) 1990-05-31 2000-07-20 Protein D fra Haemophilus influenzae eller beslektede Haemophilus-arter for anvendelse in vitro, et renset antistoff som binder proteinet, samt anvendelser derav.
NO2009021C NO2009021I1 (no) 1990-05-31 2009-09-24 Protein D
NO2009022C NO2009022I1 (no) 1990-05-31 2009-09-24 Protein-D ; Se annet dokument (det siste)

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20003716A NO322330B1 (no) 1990-05-31 2000-07-20 Protein D fra Haemophilus influenzae eller beslektede Haemophilus-arter for anvendelse in vitro, et renset antistoff som binder proteinet, samt anvendelser derav.
NO2009021C NO2009021I1 (no) 1990-05-31 2009-09-24 Protein D
NO2009022C NO2009022I1 (no) 1990-05-31 2009-09-24 Protein-D ; Se annet dokument (det siste)

Country Status (15)

Country Link
US (9) US5989828A (no)
EP (1) EP0594610B1 (no)
JP (1) JP3066072B2 (no)
AT (1) ATE170531T1 (no)
AU (1) AU650011B2 (no)
CA (1) CA2083172C (no)
DE (3) DE69130116T2 (no)
DK (1) DK0594610T3 (no)
ES (1) ES2119776T3 (no)
FI (1) FI109029B (no)
LU (2) LU91609I2 (no)
NL (2) NL300409I2 (no)
NO (4) NO309721B1 (no)
SE (1) SE466259B (no)
WO (1) WO1991018926A1 (no)

Families Citing this family (271)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466259B (sv) * 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
SE9201331D0 (sv) * 1992-04-28 1992-04-28 Hightech Receptor C O Active Protein l och hybridproteiner daerav
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US20020055101A1 (en) 1995-09-11 2002-05-09 Michel G. Bergeron Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
US6001564A (en) * 1994-09-12 1999-12-14 Infectio Diagnostic, Inc. Species specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
JPH11508225A (ja) * 1995-04-17 1999-07-21 ヘンリー エム．ジャクソン ファンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン 細菌のリポ蛋白質を用いた多糖類に対する免疫応答の誘導および増強
US5994066A (en) * 1995-09-11 1999-11-30 Infectio Diagnostic, Inc. Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
US20030049636A1 (en) 1999-05-03 2003-03-13 Bergeron Michel G. Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
US20050033022A1 (en) * 1997-09-26 2005-02-10 Smithkline Beecham Biologicals Sa Fusion proteins comprising HIV-1 Tat and/or Nef proteins
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
EP1584685B1 (en) 1998-02-05 2011-04-13 GlaxoSmithKline Biologicals SA Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with T-helper epitopes and of compositions for vaccination
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6482597B1 (en) 1999-12-17 2002-11-19 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6312695B1 (en) 1998-03-18 2001-11-06 Corixa Corporation Compounds and methods for therapy of lung cancer
US6426072B1 (en) 2000-08-02 2002-07-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6518256B1 (en) 1998-03-18 2003-02-11 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7049063B2 (en) 1998-03-18 2006-05-23 Corixa Corporation Methods for diagnosis of lung cancer
US6531315B1 (en) 1998-03-18 2003-03-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6660838B1 (en) 1998-03-18 2003-12-09 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6960570B2 (en) 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US6696247B2 (en) 1998-03-18 2004-02-24 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6821518B1 (en) 1998-03-18 2004-11-23 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6706262B1 (en) 1998-03-18 2004-03-16 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6342231B1 (en) * 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
CA2336523C (en) 1998-08-07 2015-06-30 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
TR200102500T2 (tr) 1998-12-08 2002-03-21 Corixa Corporation Chlamydia enfeksiyonunu tedavi etmek i‡in bileçikler.
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
CA2363118A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
EP1163000B1 (en) 1999-03-19 2008-02-27 GlaxoSmithKline Biologicals S.A. Vaccine against antigens from bacteriae
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
YU72901A (sh) 1999-04-02 2004-07-15 Corixa Corporation Preparati za primenu u terapiji i dijagnozi raka pluća
US20040040205A1 (en) * 2002-04-25 2004-03-04 Weder Donald E. Wrapper with decorative extension and method
CA2937907C (en) 1999-09-28 2017-08-22 Geneohm Sciences Canada Inc. Nucleic acids, methods and kits for the detection of campylobacter
CZ303468B6 (cs) 2000-02-23 2012-10-03 Smithkline Beecham Biologicals S. A. Imunogenní smes a farmaceutická smes
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030175700A1 (en) 2000-04-21 2003-09-18 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
DK1542732T3 (da) 2000-06-20 2009-12-14 Corixa Corp Fusionsproteiner af Mycobacterium tuberculosis
ATE396265T1 (de) 2000-06-28 2008-06-15 Corixa Corp Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
SK288007B6 (sk) 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
US7713544B2 (en) * 2000-07-28 2010-05-11 Emory University Biological component comprising artificial membrane
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0025171D0 (en) * 2000-10-13 2000-11-29 Smithkline Beecham Biolog Novel compounds
ES2392943T3 (es) 2000-10-18 2012-12-17 Glaxosmithkline Biologicals S.A. Vacunas antitumorales
GB0025998D0 (en) * 2000-10-24 2000-12-13 Smithkline Beecham Biolog Novel compounds
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
EP1383896A2 (en) * 2001-04-30 2004-01-28 GlaxoSmithKline Biologicals S.A. Haemophilus influenzae antigens
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
ES2358642T3 (es) * 2001-11-07 2011-05-12 Mannkind Corporation Vectores de expresión que codifican epítopos de antígenos y métodos para su diseño.
DK1581119T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
DE60335755D1 (de) 2002-07-18 2011-02-24 Univ Washington Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
RU2544850C2 (ru) 2003-01-06 2015-03-20 Корикса Корпорейшн Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
EP2289546A3 (en) 2003-01-30 2011-03-30 Novartis Vaccines and Diagnostics S.r.l. Injectable vaccines against multiple meningococcal serogroups
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ATE506963T1 (de) 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
JP2005112827A (ja) * 2003-10-10 2005-04-28 National Institute Of Advanced Industrial & Technology 抗体アフィニティ担体
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP2199801B1 (en) 2004-07-14 2013-05-29 The Regents of The University of California Biomarkers for early detection of ovarian cancer
CA2580103C (en) 2004-09-22 2021-11-16 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP1858919B1 (en) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
JP2008529558A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 髄膜炎／敗血症に関連する大腸菌由来のタンパク質および核酸
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
BRPI0609547A2 (pt) 2005-03-31 2011-10-18 Glaxosmithkline Biolog Sa composição, uso de uma composição, método para o tratamento ou prevenção de infecção por chlamydia, uso de uma ou mais proteìnas de chlamydia, de fragmentos imunogênicos das mesmas ou de polinucleotìdeos codificando os mesmos, método para o tratamento ou prevenção de infecção por chlamydia, e, método para a determinação prévia de infecção por chlamydia em um indivìduo
TWI445545B (zh) 2005-04-08 2014-07-21 Wyeth Corp 多價肺炎球菌多醣-蛋白質共軛物組合物
EP1871411A4 (en) 2005-04-18 2010-07-21 Novartis Vaccines & Diagnostic EXPRESSION OF HEPATITIS B VIRUS SURFACE ANTIGEN FOR VACCINE MANUFACTURE
CA2607715C (en) 2005-04-29 2015-11-24 Glaxosmithkline Biologicals S.A. Novel method for preventing or treating m tuberculosis infection
BRPI0612669B8 (pt) 2005-06-27 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, composição, e composição liofilizada
CA2621023C (en) 2005-09-01 2019-07-02 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup c meningococcus
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US20090010959A1 (en) 2005-12-22 2009-01-08 Ralph Leon Biemans Pneumococcal Polysaccharide Conjugate Vaccine
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
UA92782C2 (ru) 2006-01-17 2010-12-10 Арне Форсгрен Новый поверхностный белок haemophilus influenzae (белок е; ре)
WO2007087576A2 (en) 2006-01-24 2007-08-02 The Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
SI2004225T1 (sl) 2006-03-22 2012-08-31 Novartis Ag Reĺ˝imi za imunizacijo z meningokoknimi konjugati
CN103169960A (zh) 2006-03-30 2013-06-26 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
EP2392672A1 (en) 2006-06-02 2011-12-07 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the CD52 gene
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
EA016417B1 (ru) 2006-09-07 2012-04-30 Глаксосмитклайн Байолоджикалс С.А. Способ получения вакцины
US8309096B2 (en) 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
NZ578285A (en) * 2007-01-15 2011-12-22 Glaxosmithkline Biolog Sa Fusion protein comprising a prame linked to a immunological fusion partner protein and additional amino acids at the n terminal end of the fusion partner sequence
MX2009010800A (es) 2007-04-04 2010-01-29 Infectious Disease Res Inst Id Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
CA2685506A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
EA201300101A1 (ru) 2007-05-24 2014-02-28 Глаксосмитклайн Байолоджикалс С.А. Лиофилизированная антигенная композиция
BRPI0813307C1 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, processo para fabricar a vacina
EP3061462B1 (en) 2007-07-02 2019-02-27 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EA017879B1 (ru) 2007-09-17 2013-03-29 Онкометилом Сайенсиз Са Улучшенное определение экспрессии mage-a
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
US9943584B2 (en) * 2008-09-17 2018-04-17 Hunter Immunology Limited Non-typeable haemophilus influenzae vaccines and their uses
EP2326992B1 (de) * 2008-09-19 2015-04-22 Schoeller Technocell GmbH & Co. KG Aufzeichnungsmaterial für laserdruckverfahren
CA2739581A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
HUE029265T2 (en) 2008-10-27 2017-02-28 Glaxosmithkline Biologicals Sa Method of purifying carbohydrates from the group streptococci
JP5209800B2 (ja) 2008-12-09 2013-06-12 ファイザー バクシーンズ エルエルシー ＩｇＥＣＨ３ペプチドワクチン
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
BRPI0923006A2 (pt) 2008-12-17 2016-03-08 Novartis Ag vacinas meningococicas incluindo receptor de hemoglobina
US7876118B2 (en) 2009-02-05 2011-01-25 Advantest Corporation Test equipment
BRPI1009873A2 (pt) 2009-03-17 2016-03-08 Glaxosmithkline Biolog Sa detecção aperfeiçoada de expressão gênica
EP2411045A1 (en) 2009-03-24 2012-02-01 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
PL2411048T3 (pl) 2009-03-24 2020-11-16 Glaxosmithkline Biologicals Sa Adjuwantowe meningokokowe białko wiążące czynnik h
SI3281947T1 (sl) 2009-04-03 2020-07-31 The University Of Chicago Sestave in metode v zvezi z variantami proteina A (SPA)
WO2011127032A1 (en) 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
BRPI1014494A2 (pt) 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
CA2768346A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
NZ620441A (en) 2009-09-03 2015-08-28 Pfizer Vaccines Llc Pcsk9 vaccine
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
ES2812523T3 (es) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
CA2779578A1 (en) 2009-10-30 2011-05-05 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
HUE031184T2 (en) 2010-01-27 2017-06-28 Glaxosmithkline Biologicals Sa Modified tuberculosis antigens
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012057904A1 (en) 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
EA201390676A1 (ru) 2010-11-08 2013-11-29 Инфекшес Дизиз Рисерч Инститьют Вакцины, содержащие полипептиды неспецифической нуклеозидгидролазы и стерол 24-c-метилтрансферазы (smt), для лечения и диагностики лейшманиоза
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
WO2012103353A2 (en) 2011-01-26 2012-08-02 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective detection of haemophilus influenzae
ES2612511T3 (es) 2011-01-27 2017-05-17 Glaxosmithkline Biologicals Sa Nanoemulsiones de adyuvante con inhibidores de cristalización
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
BR112013022397A2 (pt) 2011-03-02 2017-09-26 Derek O’Hagan vacinas combinadas com doses menores de antígeno e/ou adjuvante
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
ES2785108T3 (es) 2011-03-24 2020-10-05 Glaxosmithkline Biologicals Sa Nanoemulsiones adyuvantes con fosfolípidos
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
WO2012170356A1 (en) 2011-06-04 2012-12-13 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
EP2734539A1 (en) 2011-07-22 2014-05-28 GlaxoSmithKline Biologicals S.A. Prame purification
AU2012301955A1 (en) 2011-08-29 2014-03-06 The Regents Of The University Of California Use of HDL-related molecules to treat and prevent proinflammatory conditions
GB201114919D0 (en) 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
CN104159603A (zh) 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2910319C (en) 2012-04-26 2022-06-14 University Of Chicago Staphylococcal coagulase antigens and methods of their use
CN104736180A (zh) 2012-05-22 2015-06-24 诺华股份有限公司 脑膜炎球菌血清组x偶联物
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
JP2015525784A (ja) 2012-08-03 2015-09-07 インフェクティアス ディジーズ リサーチ インスティチュート 活動性結核菌感染を治療するための組成物及び方法
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
RU2015106745A (ru) 2012-10-03 2016-11-27 Глэксосмитклайн Байолоджикалз Са Иммуногенные композиции
CA2886938A1 (en) 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Non-cross-linked acellular pertussis antigens for use in combination vaccines
ES2656510T3 (es) 2012-11-30 2018-02-27 Glaxosmithkline Biologicals S.A. Antígenos de Pseudomonas y combinación de antigenos
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
WO2014160987A2 (en) 2013-03-28 2014-10-02 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR102049825B1 (ko) 2014-01-21 2019-12-03 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
PL3096783T3 (pl) 2014-01-21 2021-12-13 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
SG11201604728XA (en) 2014-01-21 2016-08-30 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015121783A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
LT3110442T (lt) 2014-02-28 2020-12-28 Glaxosmithkline Biologicals Sa Modifikuoti meningokokinio fhbp polipeptidai
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
MX2017009308A (es) 2015-01-15 2017-11-08 Pfizer Composiciones inmunogenicas para usar en vacunas neumococicas.
EP3270897A4 (en) 2015-03-20 2018-12-05 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
PE20180657A1 (es) 2015-07-21 2018-04-17 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP3383426A1 (en) 2015-12-04 2018-10-10 Dana Farber Cancer Institute, Inc. Vaccination with mica/b alpha 3 domain for the treatment of cancer
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
WO2017205225A2 (en) 2016-05-21 2017-11-30 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
EP3269385A1 (en) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
EP3474890A1 (en) 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. Pneumococcal polysaccharide-protein conjugate composition
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
EP3551668A1 (en) 2016-12-06 2019-10-16 GlaxoSmithKline Biologicals S.A. Purification process for capsular polysaccharide
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
HRP20220573T1 (hr) 2017-01-20 2022-06-10 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima
WO2018144438A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US11167022B2 (en) 2017-03-31 2021-11-09 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
EP3630176A1 (en) 2017-05-30 2020-04-08 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
EP3641808A1 (en) * 2017-08-14 2020-04-29 GlaxoSmithKline Biologicals S.A. Methods of boosting immune responses
KR20200051004A (ko) 2017-09-07 2020-05-12 머크 샤프 앤드 돔 코포레이션 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
PE20201338A1 (es) 2017-12-06 2020-11-25 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos
US20210269603A1 (en) 2018-07-19 2021-09-02 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
JP2022513458A (ja) 2018-12-12 2022-02-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
CN113453708A (zh) 2018-12-19 2021-09-28 默沙东公司 包含肺炎链球菌多糖-蛋白缀合物的组合物及其使用方法
EP3923982A1 (en) 2019-02-11 2021-12-22 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3956666A1 (en) 2019-04-18 2022-02-23 GlaxoSmithKline Biologicals S.A. Antigen binding proteins and assays
US20220211859A1 (en) 2019-05-10 2022-07-07 Glaxosmithkline Biologicals Sa Conjugate production
EP3980044A1 (en) 2019-06-05 2022-04-13 GlaxoSmithKline Biologicals SA Saponin purification
JP2022542316A (ja) 2019-07-31 2022-09-30 サノフィ パスツール インコーポレイテッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物およびその使用方法
JP2022543264A (ja) 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロテインｄポリペプチドを含む組成物を調製するプロセス
BR112021026565A2 (pt) 2019-08-05 2022-05-03 Glaxosmithkline Biologicals Sa Composição imunogênica
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN114667343A (zh) 2019-11-01 2022-06-24 辉瑞大药厂 大肠杆菌组合物及其方法
EP4061412A1 (en) 2019-11-22 2022-09-28 GlaxoSmithKline Biologicals S.A. Dosage and administration of a bacterial saccharide glycoconjugate vaccine
CN115362177A (zh) 2020-02-21 2022-11-18 辉瑞公司 糖类的纯化
CA3173729A1 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021250626A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
CA3199610A1 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4333879A1 (en) 2021-05-03 2024-03-13 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
AU2022281543A1 (en) 2021-05-28 2023-11-23 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3231684A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800798A (en) * 1972-07-11 1974-04-02 A Winkler Hydrophobic catheter construction
DE2322533C2 (de) * 1972-11-06 1986-08-28 Pharmacia AB, Uppsala Verfahren zum Binden von Immunoglobulin und Hilfsmittel zur Durchführung des Verfahrens
SE451596B (sv) * 1983-06-22 1987-10-19 Excorim Kb Forfarande for utvinning av protein g
SE459503B (sv) * 1985-05-03 1989-07-10 Excorim Kommanditbolag Hybrid-dna-molekyl innefattande dna-sekvens som kodar foer protein g samt foerfarande foer framstaellning av protein g
SE459662B (sv) * 1986-03-21 1989-07-24 Pharmacia Ab Hybrid-dna-molekyl som kodar foer ett protein med samma igg specificitet som protein g, plasmid innehaallande densamma samt foerfarande foer framstaellning av proteinet
US5173294A (en) * 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
AU623353B2 (en) * 1987-12-10 1992-05-14 Board Of Regents, The University Of Texas System Methods and compositions for the production of haemophilus influenzae type b major outer membrane protein antigens
ATE105189T1 (de) * 1988-04-19 1994-05-15 American Cyanamid Co Haemophilus influenzae typ b polysaccharidaussermembranprotein-konjugat als impfstoff.
USRE37919E1 (en) 1989-05-12 2002-12-03 The General Hospital Corporation Recombinant DNA method for production of parathyroid hormone
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US6680057B1 (en) 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor

Also Published As

Publication number Publication date
SE466259B (sv) 1992-01-20
EP0594610A1 (en) 1994-05-04
US7666621B2 (en) 2010-02-23
US5858677A (en) 1999-01-12
EP0594610B1 (en) 1998-09-02
DE69130116T2 (de) 1999-02-18
FI925460A0 (fi) 1992-11-30
US20100209905A1 (en) 2010-08-19
US6025484A (en) 2000-02-15
DE122009000060I1 (de) 2011-12-01
NO20003716L (no) 1992-11-30
NO309721B1 (no) 2001-03-19
DE122009000059I1 (de) 2010-04-29
NO2009021I1 (no) 2009-10-12
CA2083172C (en) 2002-07-02
NO322330B1 (no) 2006-09-18
WO1991018926A1 (en) 1991-12-12
LU91610I2 (fr) 2009-11-24
US20070071774A1 (en) 2007-03-29
ES2119776T3 (es) 1998-10-16
DK0594610T3 (da) 1998-11-02
CA2083172A1 (en) 1991-12-01
AU7559391A (en) 1991-12-31
AU650011B2 (en) 1994-06-09
NO2009022I1 (no) 2009-10-12
ATE170531T1 (de) 1998-09-15
NL300409I2 (nl) 2010-03-01
US7115271B1 (en) 2006-10-03
DE69130116D1 (de) 1998-10-08
FI109029B (fi) 2002-05-15
JP3066072B2 (ja) 2000-07-17
US6139846A (en) 2000-10-31
NO20003716D0 (no) 2000-07-20
US5888517A (en) 1999-03-30
FI925460A (fi) 1992-11-30
US5989828A (en) 1999-11-23
NL300410I1 (nl) 2009-12-01
SE9001949D0 (sv) 1990-05-31
NL300409I1 (nl) 2009-12-01
LU91609I2 (fr) 2009-11-24
USRE41277E1 (en) 2010-04-27
SE9001949L (sv) 1991-12-01
NO924507L (no) 1992-11-30
JPH05507465A (ja) 1993-10-28

Similar Documents

Publication Publication Date Title
NO924507D0 (no) Protein fra haemophilus influenzae
Une et al. Roles of V antigen in promoting virulence and immunity in yersiniae.
CA1152000A (en) Immunization against dental caries with glucosyltransferase antigens
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
CA2047681A1 (en) Vaccines for nontypable haemophilus influenzae
RU94024561A (ru) Иммунореактивные композиции, способ получения композиции, способы получения и обнаружения антител, набор днк, клетка-хозяин, способ получения белка
DE262192T1 (de) Verfahren und mittel zur herstellung eines proteins mit dergleichen igg-spezifizitaet wie protein g.
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
CA2217522A1 (en) Isolated frpb nucleic acid molecule and vaccine
Smith et al. Antigenic relatedness of glucosyltransferase enzymes from Streptococcus mutans
DE69627150T2 (de) Verfahren zur herstellung von gegen e.coli bakterien der familie cs4-cfa/1 gerichteten antikörpern
DE3752131T2 (de) Impfstoffe und diagnosetest für haemophilus influenzae
ATE82985T1 (de) Strukturelles phosphoprotein (pp 150) des menschlichen cytomegalovirus, seine herstellung und verwendung.
EP0177814A3 (en) Peptide antibodies and their use in detecting oncogene products
Fukui et al. Acceleration of dextransucrase activity of Streptococcus mutans by secretory immunoglobulin A
Carding et al. Multiple proteins related to the soluble galactose-binding animal lectin revealed by a monoclonal anti-lectin antibody
CA2006587A1 (en) Membrane proteins and peptides of haemophilus influenzae type b
Johnson Characterization of group A streptococcal R-28 antigen purified by hydroxyapatite column chromatography
Bolivar Immunological crossreactivity of Paramecium surface antigens: conformational differences account for cell surface specificity.
Straus et al. Immunochemistry and end-group analyses of group A streptococcal M proteins

Legal Events

Date Code Title Description
MK1K Patent expired